Costimulation targeting therapies in organ transplantation

Current Opinion in Organ Transplantation

Volumn 13, Issue 6, 2008, Pages 622-626

  Gandhi, Anshul M ^a   Fazli, Umer ^a   Rodina, Valentina ^a   Qazi, Yasir A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Belatacept; Costimulation blockade; Organ transplantation

Indexed keywords

ABATACEPT; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CHI 220; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; RAPAMYCIN; STEROID; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE;

CARDIOVASCULAR DISEASE; CELL STIMULATION; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; METABOLIC DISORDER; NEPHROTOXICITY; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG COMBINATION; DRUG EFFECT; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; ORGAN TRANSPLANTATION; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; ORGAN TRANSPLANTATION; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 60849096691     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283193beb     Document Type: Review

References (35)

1. Larsen C, Pearson T, Adams A, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA-4Ig with potent immunosuppressive properties. Am J Transplant 2005; 5:443-453.
2. Vincenti F. Costimulation blockade in autoimmunity and transplantation. J Allergy Clin Immunol 2008; 121:299-306.
3. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353:770-781.
4. Chavez H, Beaudreuil S, Abbed K, et al. Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with belatacept mediated CD28-CD80/86 blockade. Transpl Immunol 2007; 17:243-248.
5. Ingelfinge JR, Schwartz RS. Immunosuppression- the promise of specificity. N Engl J Med 2005; 353:836-839.
6. Pree I, Wekerle T. New approaches to prevent transplant rejection: costimulation blockers anti-CD40L and CTLA4Ig. Drug Discov Today Ther Strateg 2006; 3:41-47.
7. Eisen HJ. Immunosuppression on the horizon. Heart Fail Clin 2007; 3:43-49.
8. Vincenti F, Luggen M. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu Rev Med 2007; 58:347-358.
9. Larsen CP, Knechtle SJ, Adams A, et al. A new look at blockade of T-cell costimulation: a therapeutic strategy for long term maintenance immunosuppression. Am J Transplant 2006; 6 (5 Pt 1):876-883.
10. Vincenti F. Costimulation blockade - what will the future bring? Nephrol Dial Transplant 2007; 22:1293-1296.
11. Venetz JP, Pascual M. New treatments for acute humoral rejection of kidney allografts. Expert Opin Investig Drugs 2007; 16:625-633.
12. Créput C, Durrbach A, Deroure B, Charpentier B. New therapeutic targets for antibodies and recombinant proteins in organ transplantation. CurrOpin Mol Ther 2007; 9:153-159.
13. Yabu JM, Vincenti F. Novel immunosuppression: small molecules and biologics. Semin Nephrol 2007; 27:479-486.
14. Vincenti F. Protein therapies and antiproliferatives: a new paradigm in immunosuppression. Transplant Rev 2005; 19:179-185.
15. Kokko KE, Newell KA, Pearson TC, Larsen CP. Enhanced immunosuppression induced by targeted mutation of cytotoxic T lymphocyte antigen 4-immunoglobulin. Curr Opin Org Transplant 2005; 10:265-269.
16. Moudgil A. Induction therapy in pediatric renal transplant recipients: an overview. Pediatr Drugs 2007; 9:323-341.
17. Linsley PS, Greene JL, Brady W, et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994; 1:793-801.
18. McIntyre JA, Fernande D. Belatacept: treatment of transplant rejection. Drugs Future 2005; 30:873-876.
19. Vanhove B, Soulillou JP. Technology evaluation: belatacept, Bristol-Myers Squibb. Curr Opin Mol Ther 2005; 7:384-393.
20. Davis PM, Nadler S, Suchard S. Belatacept does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. Am J Transplant 2008; 8 (Suppl 2):619.
21. Silva HT Jr, Machado PP, Felipe CR, Pestana JOM. Immunotherapy for de novo renal transplantation. Drugs 2006; 66:1665-1684.
22. SayeghM,ChrandrakerA. Does belatacept provide equivalent suppression of acute renal transplant rejection to ciclosporin? Nat Clin Pract Nephrol 2006; 2:134-135.
23. Vincenti F. Current use and future trends in induction therapy. Saudi J Kidney Dis Transpl 2005; 16:506-513.
24. Hirose R, Vincenti F. Immunosuppression: today, tomorrow, and withdrawal. Semin Liver Dis 2006; 26:201-210.
25. Kean LS, Gangappa S, Pearson TC, Larsen CP. Transplant tolerance in nonhuman primates: progress, current challenges and unmet needs. Am J Transplant 2006; 6 (5 Pt 1):884-893.
26. Emamaullee JA, Merani S, Larsen CP, Shapiro AMJ. Belatacept and basilix-imab diminish human antiporcine xenoreactivity and synergize to inhibit alloimmunity. Transplantation 2008; 85:118-124.
27. Adams AB, Shirasugi Nozumu, Durham MM, et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogenic islets in nonhuman primates. Diabetes 2002; 51: 265-270.
28. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997; 94:8789-8794.
29. Kirk A, Knechtle SJ, Sollinger HW, et al. Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation. Am J Transplant 2001; 1 (Suppl 1):191.
30. AdamsAB, ShirasugiN, Jones TR, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005; 174:542-550.
31. Davis PM, Nadler S, Suchard S. Belatacept modulates T-cell proliferation and effector function independent of IDO induction. Am J Transplant 2008; 8 (Suppl 2):620.
32. Löb S, Königsrainer A. Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction? Langenbecks Arch Surg 2007. 10.1007/ s00423-007-0245-7.
33. Yabu JL, Liu W, Putnam A, et al. Effect of belatacept on circulating and intragraft regulatory T cells in kidney transplant patients. Am J Transplant 2008; 8 (Suppl 2):282.
34. Takahasi K, Kawai M, Soma T, et al. The importance of persisting allostimulation for the maintenance of tolerance and regulatory T-cells. Am J Transplant 2008; 8 (Suppl 2):407.
35. Suntharalingam G, Perry M, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018-1028.